BUPHENYL ® is a registered trademark of Ucyclyd Pharma, Inc.
CONTACT: Shari Annes, Investor Relations Cell: 650 888 0902
Under proposed transaction's terms, Horizon Pharma would acquire all outstanding shares of Depomed for $29.25 each in an all-stock transaction, a 42% premium to its closing price on Monday.
Large pharmas continued the shopping spree, paying no attention to whispers of a biotech bubble.
Stocks recapture positive territory for the year.